Frankfurt
30.03.26 | 15:25
11,100 Euro
+0,91 % +0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million | 2 | GlobeNewswire (USA) | ||
| 23.02. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | 355 | GlobeNewswire (Europe) | MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium... ► Artikel lesen | |
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 23.02. | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 16.01. | Weekly Buzz: Lyra Therapeutics Slashes Jobs; FDA Okays Fortress Biotech's ZYCUBO; Boston Scientific To Acquire Penumbra; BriaCell Therapeutics On Watch | 713 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes... ► Artikel lesen | |
| 14.01. | Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease | 13 | Pharmaceutical Technology | ||
| 13.01. | Fortress Bio gains on FDA approval of copper replacement therapy | 6 | Seeking Alpha | ||
| 13.01. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | 821 | GlobeNewswire (Europe) | Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million... ► Artikel lesen | |
| 15.12.25 | FDA sets new PDUFA date for Fortress Biotech's Menkes disease therapy | 31 | Investing.com | ||
| 15.12.25 | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.11.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 687 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 14.11.25 | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.11.25 | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.25 | Fortress Biotech Q3 Earnings Preview | 5 | Seeking Alpha | ||
| 21.10.25 | Fortress Biotech: Aktie legt zu - Gichtmittel der Tochtergesellschaft erreicht Phase-3-Studie | 16 | Investing.com Deutsch | ||
| 21.10.25 | Fortress Biotech stock rises after subsidiary's gout treatment enters Phase 3 trials | 3 | Investing.com | ||
| 21.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 307 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 02.10.25 | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 20 | Investing.com Deutsch | ||
| 02.10.25 | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 177 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 284,10 | -0,18 % | Stryker, Zimmer Biomet & mehr Dividenden im global market - Ex-Tag 31.03.2026 | ||
| REGENERON PHARMACEUTICALS | 653,40 | -0,09 % | Sanofi: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid | Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Approval in moderate-to-severe patients was based on pivotal study results... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,190 | +0,27 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,225 | +0,49 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 37,200 | +0,54 % | Tempus AI Enters Collaboration With Daiichi Sankyo | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Tempus AI announced a strategic collaboration with Daiichi Sankyo (4568.T) for accelerating the clinical development and differentiation of an antibody drug... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,412 | +6,19 % | Sonderausgabe: "Must Have"-Biotech-Stock?! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,113 | +1,62 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| IMMUNITYBIO | 5,774 | -0,59 % | ImmunityBio-Aktie -21%: Buy the dip? | Es ist eine nervenaufreibende Woche für ImmunityBio-Aktionäre. Nachdem der Kurs des Biotech-Unternehmens am Montag +10% in die Höhe schoss, ging es am gestrigen Dienstag um atemberaubende -21% nach... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,845 | -3,56 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| GINKGO BIOWORKS | 4,860 | +1,67 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Ginkgo provides an update on its fourth quarter financial results
BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,921 | +0,65 % | BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters | ||
| CYTOMX THERAPEUTICS | 3,824 | -0,31 % | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | ||
| SANA BIOTECHNOLOGY | 2,670 | -3,61 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 46,000 | -0,43 % | HBM verdient an Übernahme des Krebsspezialisten Terns | Zug - Die auf den Gesundheitssektor spezialisierte Beteiligungsgesellschaft HBM Healthcare Investments macht Kasse bei der Übernahme des kalifornischen Krebsspezialisten Terns durch den US-Pharmakonzern... ► Artikel lesen | |
| BIOMEA FUSION | 1,320 | +0,76 % | Biomea Fusion, Inc.: Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights | Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+0,91 %) liegt der Kurs bei 11,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.